Advisor Group’s Pacific Biosciences PACB Stock Holding History

Advisor Group’s Portfolio PACB Stock Details PACB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-3,932	Closed	-$10K	–	5035
2017 Q4	$10K	Buy	+3,932	New	+$13.8K	﹤0.01%	4089

Other funds holding PACB

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

OIM

Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return

RCM

Raging Capital Management Rocky Hill, New Jersey $18.2M AUM 17.75% 1-Year Est. Return

Advisor Group's PACB Position: Q1 2018 in Review

Advisor Group sold out of Pacific Biosciences (PACB) in Q1 2018, closing a stake of 3,932 shares — an estimated $10K sold.

Advisor Group first reported a position in PACB in Q4 2017 and held it in 1 quarter. The position peaked at $10K in Q4 2017. 101 funds tracked by Wall St. Rank hold PACB as of Q1 2018.

Advisor Group reported no remaining Pacific Biosciences position as of Q1 2018 after selling out during the quarter.
Advisor Group sold 3,932 Pacific Biosciences shares in Q1 2018, an estimated $10K.
Advisor Group first reported a position in Pacific Biosciences in Q4 2017 and held it in 1 quarter.
Advisor Group's Pacific Biosciences position peaked at $10K in Q4 2017.
101 funds tracked by Wall St. Rank held Pacific Biosciences as of Q1 2018.

Based on Advisor Group's 13F filing for Q1 2018, filed 15 May 2018.